Moderna, Inc. (NASDAQ: MRNA) reported second quarter 2023 earnings results today.
Total revenue dropped to $344 million from $4.7 billion in the same period last year, mainly due to a decrease in sales of the company’s COVID-19 vaccine.
Net loss was $1.4 billion, or $3.62 per share, compared to net income of $2.2 billion, or $5.24 per share, last year.
Product sales were $293 million, down 94% compared to last year, mainly due to lower sales volume. The company reported $0.3 billion in COVID-19 vaccine sales in Q2.
For FY2023, the company is expecting COVID-19 sales of $6-8 billion, dependent on US vaccination rates.
Most Popular
After a positive year, what’s in the cards for Electronic Arts (EA) in FY25
Electronic Arts (NASDAQ: EA) ended fiscal 2024 on a mixed note, reporting lower revenues and improved bottom-line performance for the fourth quarter. The stock declined following the announcement as earnings
A look at how Disney’s (DIS) entertainment business performed in Q2 2024
Shares of the Walt Disney Company (NYSE: DIS) stayed green on Wednesday. The stock has gained 16% year-to-date. The company recorded revenue and earnings growth for the second quarter of
Uber Technologies reports wider loss for Q1 2024; revenue up 15%
Uber Technologies, Inc. (NYSE: UBER) on Wednesday reported a wider net loss for the first quarter of 2024. Revenues of the ride-sharing giant increased 15% during the three months. Net
